BPC June 15 update

180 Life Sciences ATNF Regulatory update; Clovis CLVS Phase 1 data

Pre-Market Updates

Yesterday''s BIOrdle ticker was CMPI. Checkmate Pharmaceuticals (NASDAQ: CMPI) is a biotech company that was recently acquired by Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) for approximately $250 million.

__________________________

180 Life Sciences Corp. (NASDAQ: ATNF) released an update from its meeting with the FDA regarding adalimumab to treat Dupuytren's disease, noting that its planned pivotal trial did not have proposed outcome measures sufficient to demonstrate efficacy.

Evoke Pharma, Inc. (NASDAQ: EVOK) announced that the Florida Medicaid Pharmaceutical & Therapeutics Committee has approved adding GIMOTI to treat acute and recurrent diabetic gastroparesis to the Florida Medicaid Preferred Drug List (PDL) effective immediately.

MorphoSys AG (NASDAQ: MOR) and Human Immunology Biosciences, Inc. announced that they entered into a deal for HIBio to develop and commercialize MorphoSys' felzartamab and MOR210 in exchange for a 15% equity stake in HIBio and up to $1 billion in milestone payments to MorphoSys.

Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) priced its public offering of 10,000,000 shares of stock at $15.00 per share. The gross proceeds are expected to be $150 million.

Clovis Oncology (NASDAQ: CLVS) announced initial Phase 1 data for its radionuclide therapy FAP-2286 in solid tumors, one patient out of nine treated with the experimental therapy developed a confirmed partial response.

BioCardia, Inc. (NASDAQ: BCDA) announced that the United States Patent Office has granted a patent covering an image guided delivery of treatments for the heart, and procedures using interventional biotherapeutic delivery technologies to deliver biologics to specific target sites.

Immunic, Inc. (NASDAQ: IMUX) announced that data from its Phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) to treat multiple sclerosis (RRMS) was published in the Annals of Clinical and Translational Neurology. The data reiterated that the trial met its primary and key secondary endpoints, while also being safe for patient use.

Pre-Market Advancers

CompanyPriceChange
TALS
Talaris Therapeutics Inc.
$1.01 +1.01  +100%
AKUS
Akouos Inc.
$1.01 +1.01  +100%
QNRX
Quoin Pharmaceuticals Ltd.
$1.01 +1.01  +100%
BBI
Brickell Biotech, Inc.
$1.01 +1.01  +100%
AKBA
Akebia Therapeutics Inc.
$1.01 +1.01  +100%
ALNA
Allena Pharmaceuticals Inc.
$1.01 +1.01  +100%
PRVB
Provention Bio Inc.
$1.01 +1.01  +100%
IVC
Invacare Corporation
$1.01 +1.01  +100%
ENSC
Ensysce Biosciences Inc.
$1.01 +1.01  +100%
BNTC
Benitec Biopharma Inc.
$1.01 +1.01  +100%

Pre-Market Decliners

CompanyPriceChange
CADL
Candel Therapeutics Inc.
$1.01 -1.01  -100%
CLVS
Clovis Oncology Inc.
$1.01 -1.01  -100%
ENDP
Endo International plc
$1.01 -1.01  -100%
TYRA
Tyra Biosciences Inc.
$1.01 -1.01  -100%
CTKB
Cytek Biosciences Inc.
$1.01 -1.01  -100%
BLTE
Belite Bio Inc
$1.01 -1.01  -100%
MREO
Mereo BioPharma Group plc
$1.01 -1.01  -100%
CRTX
Cortexyme Inc.
$1.01 -1.01  -100%
PULM
Pulmatrix Inc.
$1.01 -1.01  -100%
RXST
RxSight Inc.
$1.01 -1.01  -100%